Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Prognostic Importance of Cytogenetic Subgroups in Relapse Risk Stratification in Children and Young Adults with First Relapsed B-ALL: A Children's Oncology Group Study AALL1331

Teena Bhatla, Laura Hogan, Xinxin Xu, Lingyun Ji, Andrew J. Carroll, Nyla A. Heerema, Mary Shago, Lia Gore, James A. Whitlock, Stephen P. Hunger, Mignon L. Loh, Patrick A. Brown

Blood (2022) 140 (Supplement 1): 3476–3477.

https://doi.org/10.1182/blood-2022-166523

Published: 2022

Journal Articles

A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A -Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children's Oncology Group (COG) Trial AALL15P1

Erin Guest, John Kairalla, Meenakshi Devidas, Emily Hibbitts, Andrew J. Carroll, Nyla A. Heerema, Holly Kubaney, Amanda August, Melinda Pauly, Daniel Wechsler, Rodney R. Miles, Joel M. Reid, Cynthia Kihei, Lia Gore, Elizabeth A. Raetz, Stephen P. Hunger, Mignon L. Loh, Patrick A. Brown

Blood (2022) 140 (Supplement 1): 3256–3257.

https://doi.org/10.1182/blood-2022-167765

Published: 2022

Journal Articles

Subtype Dependent Drug Resistance Alterations in Relapsed Childhood B-ALL: A Children's Oncology Group Study

Xiaotu Ma, Lingyun Ji, Yanling Liu, Ying Shao, Heather Mulder, Pandurang Kolekar, Quang Tran, Jinghui Zhang, John Easton, William L. Carroll, Patrick A. Brown, Mignon L. Loh

Blood (2022) 140 (Supplement 1): 1048–1049.

https://doi.org/10.1182/blood-2022-166489

Published: 2022

Journal Articles

Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults

Blood (2022) 140 (Supplement 1): 4661–4663.

https://doi.org/10.1182/blood-2022-169603

Published: 2022

Journal Articles

Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell–like blasts in KMT2A -rearranged leukemia

Blood (2022) 139 (14): 2198–2211.

https://doi.org/10.1182/blood.2021013442

Published: 2022

Includes: Supplemental data

Journal Articles

Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia

Blood (2021) 138 (21): 2138–2142.

https://doi.org/10.1182/blood.2021012392

Published: 2021

Journal Articles

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331

Patrick A. Brown, Lingyun Ji, Xinxin Xu, Meenakshi Devidas, Laura Hogan, Teena Bhatla, Michael Borowitz, Elizabeth A. Raetz, Lia Gore, James A. Whitlock, Stephen P. Hunger, Mignon L. Loh

Blood (2021) 138 (Supplement 1): 363.

https://doi.org/10.1182/blood-2021-147946

Published: 2021

Journal Articles

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 256.

https://doi.org/10.1182/blood-2021-153336

Published: 2021

Journal Articles

Single-Cell Genomic Analysis Identifies Prognostically Significant Gene Expression Programs in Infant Acute Lymphoblastic Leukemia

Irina Pushel, Midhat S. Farooqi, Byunggil Yoo, Daniel Louiselle, Tomi Pastinen, Patrick A. Brown, Erin Guest

Blood (2021) 138 (Supplement 1): 3480.

https://doi.org/10.1182/blood-2021-152828

Published: 2021

Journal Articles

Single-Cell Multiomics Reveals Increased Plasticity, Resistant Populations and Stem-Cell-like Blasts in KMT2A-Rearranged Leukemia

Blood (2021) 138 (Supplement 1): 2203.

https://doi.org/10.1182/blood-2021-146102

Published: 2021

Journal Articles

Acute Leukemia and COVID-19: The Johns Hopkins Experience

Karin Paige Miller, Patrick A. Brown, B. Douglas Smith, Jonathan Webster, Helen Powell, Amy S. Duffield

Blood (2021) 138 (Supplement 1): 4046.

https://doi.org/10.1182/blood-2021-153474

Published: 2021

Journal Articles

Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival

Agne Taraseviciute, MD, Seth M. Steinberg, PhD, Regina M. Myers, MD, Lia Gore, MD, Adam J. Lamble, MD, Patrick A. Brown, MD, Jennifer Sheppard, Bonnie Yates, NP, Perry Chung, MD, Lee Chen, Colleen Annesley, MD, Deepa Bhojwani, MD, Theodore W. Laetsch, MD, Rebecca A Gardner, MD, Susan R. Rheingold, MD, Michael A Pulsipher, MD, Nirali N. Shah, MD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-139260

Published: 2020

Journal Articles

Germline Variants Associated with Cancer Predisposition and Bone Marrow Failure Are Common in KMT2A- r Infant Acute Lymphoblastic Leukemia Patients

Sarah Mc Dermott, DO, Midhat S. Farooqi, MD PhD, Azhar Saeed, MD, Byunggil Yoo, MS, Emily Farrow, PhD CGC, Neil Miller, Patrick A. Brown, MD, Erin Guest, MD

Blood (2020) 136 (Supplement 1): 41.

https://doi.org/10.1182/blood-2020-139564

Published: 2020

Journal Articles

Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-134472

Published: 2020

Journal Articles

ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Alan S. Wayne, MD, Gerard Michel, MD, Daniel W. Lee, MD, André Baruchel, MD, Sonali Chaudhury, MD, Patrick A. Brown, MD, Michelle Hermiston, MD PhD, Joerg Krueger, MD, Tong Shen, PhD, Kristy Tailford, PhD, Behzad Kharabi Masouleh, MD

Blood (2020) 136 (Supplement 1): 42.

https://doi.org/10.1182/blood-2020-137233

Published: 2020

Journal Articles

Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-136674

Published: 2020

Journal Articles

Cytogenetic Subgroups Drive Risk Stratification and Response to Chemotherapy and Blinatumomab in Children and Young Adults with Relapsed B-ALL: A Children's Oncology Group Study

Teena Bhatla, MD, Laura Hogan, MD, Xinxin Xu, MS, Lingyun Ji, Andrew J Carroll, PhD, Nyla A Heerema, PhD, Mary Shago, PhD, Lia Gore, MD, James A. Whitlock, MD, Stephen P Hunger, MD, Mignon L. Loh, MD, Patrick A. Brown, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-136364

Published: 2020

Journal Articles

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331

Patrick A. Brown, MD, Lingyun Ji, PhD, Xinxin Xu, MS, Meenakshi Devidas, PhD, Laura Hogan, MD, Michael J. Borowitz, MD PhD, Elizabeth A. Raetz, MD, Gerhard Zugmaier, Elad Sharon, MD MPH, Lia Gore, MD, James A. Whitlock, MD, Michael A. Pulsipher, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_2): LBA-1.

https://doi.org/10.1182/blood-2019-132435

Published: 2019

Journal Articles

Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031

Jessica A. Pollard, MD, Todd A. Alonzo, PhD, Patrick A. Brown, MD, Robert B. Gerbing, Elizabeth Fox, MD, John Kim Choi, MD, Brian T. Fisher, DO, MSCE, Betsy A Hirsch, PhD, Samir Kahwash, MD, John E. Levine, MDMS, Michael R. Loken, PhD, Susana C. Raimondi, PhD, Katherine Tarlock, MD, Andrew C. Wood, MBCHB, Lillian Sung, MD PhD, Anders E. Kolb, MD, Alan S Gamis, MD MPH, Soheil Meshinchi, MD PhD, Richard Aplenc, MD PhD

Blood (2019) 134 (Supplement_1): 292.

https://doi.org/10.1182/blood-2019-129557

Published: 2019

Journal Articles

FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study

Patrick A. Brown, MD, John Kairalla, Joanne M. Hilden, MD, Zoann Eckert Dreyer, MD, Andrew J. Carroll, PhD, Nyla A. Heerema, PhD, Cindy Wang, MS, Meenakshi Devidas, PhD, William L. Carroll, MD, Elizabeth A. Raetz, MD, Mignon L. Loh, MD, Stephen P. Hunger, MD, Michael J. Borowitz, MD PhD, Donald Small, MD PhD

Blood (2019) 134 (Supplement_1): 1293.

https://doi.org/10.1182/blood-2019-130564

Published: 2019

NARROW

Prognostic Importance of Cytogenetic Subgroups in Relapse Risk Stratification in Children and Young Adults with First Relapsed B-ALL: A Children's Oncology Group Study AALL1331

A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A -Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children's Oncology Group (COG) Trial AALL15P1

Subtype Dependent Drug Resistance Alterations in Relapsed Childhood B-ALL: A Children's Oncology Group Study

Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults

Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell–like blasts in KMT2A -rearranged leukemia

Out-of-specification tisagenlecleucel does not compromise safety or efficacy in pediatric acute lymphoblastic leukemia

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Single-Cell Genomic Analysis Identifies Prognostically Significant Gene Expression Programs in Infant Acute Lymphoblastic Leukemia

Single-Cell Multiomics Reveals Increased Plasticity, Resistant Populations and Stem-Cell-like Blasts in KMT2A-Rearranged Leukemia

Acute Leukemia and COVID-19: The Johns Hopkins Experience

Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival

Germline Variants Associated with Cancer Predisposition and Bone Marrow Failure Are Common in KMT2A- r Infant Acute Lymphoblastic Leukemia Patients

Disease Burden Impacts Outcomes in Pediatric and Young Adult B-Cell Acute Lymphoblastic Leukemia after Commercial Tisagenlecleucel: Results from the Pediatric Real World CAR Consortium (PRWCC)

ZUMA-4: A Phase 1/2 Multicenter Study of KTE-X19 in Pediatric and Adolescent Patients With Relapsed/Refractory B Cell Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Real-World Treatment of Pediatric Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Using Tisagenlecleucel That Is out of Specification for Commercial Release

Cytogenetic Subgroups Drive Risk Stratification and Response to Chemotherapy and Blinatumomab in Children and Young Adults with Relapsed B-ALL: A Children's Oncology Group Study

Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031

FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only